Consistent with these data, we found that correlations between frequencies of FoxP3+Helios+ Tregs and CD4+TIM-3+ T cells in TME were stronger in advanced tumor stages, suggesting that TIM-3 could be a critical mediator in the progression of CRC and may be considered a possible therapeutic target for the treatment of CRC. The gene discussed is HAVCR2; the disease is colorectal carcinoma.